Financials All Cosmos Bio-Tech Holding Corporation

Equities

4148

KYG0232P1072

Agricultural Chemicals

End-of-day quote Taiwan S.E. 23:00:00 14/05/2024 BST 5-day change 1st Jan Change
51.5 TWD +0.59% Intraday chart for All Cosmos Bio-Tech Holding Corporation +1.18% +4.36%

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 3,471 2,651 2,491 2,568 3,439 3,160
Enterprise Value (EV) 1 3,041 1,607 1,695 2,095 3,035 2,132
P/E ratio 11.4 x 74.3 x 30.4 x 13 x 9.51 x 23.2 x
Yield 4.43% 2.42% 2.57% 3.74% 4.66% 2.03%
Capitalization / Revenue 1.29 x 1.5 x 1.52 x 1.17 x 0.93 x 1.12 x
EV / Revenue 1.13 x 0.91 x 1.03 x 0.95 x 0.82 x 0.75 x
EV / EBITDA 7.56 x 13.6 x 11.7 x 6.65 x 4.28 x 9.26 x
EV / FCF -8.83 x 2.05 x -10.1 x -6.06 x -35.4 x 2.74 x
FCF Yield -11.3% 48.7% -9.95% -16.5% -2.83% 36.5%
Price to Book 1.6 x 1.3 x 1.25 x 1.29 x 1.45 x 1.4 x
Nbr of stocks (in thousands) 64,034 64,034 64,034 64,034 64,034 64,034
Reference price 2 54.20 41.40 38.90 40.10 53.70 49.35
Announcement Date 29/03/19 27/03/20 29/03/21 28/03/22 27/03/23 15/03/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 2,688 1,768 1,643 2,197 3,702 2,827
EBITDA 1 402.1 118 145.4 315 709.9 230.2
EBIT 1 356.8 73.23 102.7 273.2 667 189.9
Operating Margin 13.27% 4.14% 6.25% 12.44% 18.02% 6.72%
Earnings before Tax (EBT) 1 399 103.8 149.7 321.6 634 257.6
Net income 1 305.1 35.69 82.2 198.1 368.2 139.4
Net margin 11.35% 2.02% 5% 9.02% 9.95% 4.93%
EPS 2 4.750 0.5574 1.280 3.090 5.649 2.130
Free Cash Flow 1 -344.6 782.1 -168.5 -345.7 -85.77 777.6
FCF margin -12.82% 44.24% -10.26% -15.73% -2.32% 27.51%
FCF Conversion (EBITDA) - 662.52% - - - 337.8%
FCF Conversion (Net income) - 2,191.08% - - - 557.95%
Dividend per Share 2 2.400 1.000 1.000 1.500 2.500 1.000
Announcement Date 29/03/19 27/03/20 29/03/21 28/03/22 27/03/23 15/03/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1
Net sales 1 548.7 665.6 912 1,244 881.1 778
EBITDA - - - - - -
EBIT 1 73.58 115.3 155.1 255.1 141.5 62.37
Operating Margin 13.41% 17.32% 17.01% 20.52% 16.06% 8.02%
Earnings before Tax (EBT) - - - - - -
Net income - - - - - -
Net margin - - - - - -
EPS - - - - - -
Dividend per Share - - - - - -
Announcement Date 11/11/21 12/05/22 30/08/22 14/11/22 27/03/23 12/05/23
1TWD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 429 1,044 796 472 403 1,028
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -345 782 -169 -346 -85.8 778
ROE (net income / shareholders' equity) 14.3% 1.56% 4.1% 9.98% 17.4% 6.67%
ROA (Net income/ Total Assets) 7.88% 1.63% 2.44% 6.12% 11.8% 3.05%
Assets 1 3,873 2,189 3,364 3,239 3,127 4,571
Book Value Per Share 2 33.90 31.90 31.00 31.10 37.00 35.20
Cash Flow per Share 2 9.240 13.10 11.90 11.60 20.90 22.80
Capex 1 57.4 39.1 35 104 60.8 163
Capex / Sales 2.14% 2.21% 2.13% 4.72% 1.64% 5.76%
Announcement Date 29/03/19 27/03/20 29/03/21 28/03/22 27/03/23 15/03/24
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. 4148 Stock
  4. Financials All Cosmos Bio-Tech Holding Corporation